The oral microbiome in the pathophysiology of cardiovascular disease.
Andrea TonelliEvelyn N LumngwenaNtobeko A B NtusiPublished in: Nature reviews. Cardiology (2023)
Despite advances in our understanding of the pathophysiology of many cardiovascular diseases (CVDs) and expansion of available therapies, the global burden of CVD-associated morbidity and mortality remains unacceptably high. Important gaps remain in our understanding of the mechanisms of CVD and determinants of disease progression. In the past decade, much research has been conducted on the human microbiome and its potential role in modulating CVD. With the advent of high-throughput technologies and multiomics analyses, the complex and dynamic relationship between the microbiota, their 'theatre of activity' and the host is gradually being elucidated. The relationship between the gut microbiome and CVD is well established. Much less is known about the role of disruption (dysbiosis) of the oral microbiome; however, interest in the field is growing, as is the body of literature from basic science and animal and human investigations. In this Review, we examine the link between the oral microbiome and CVD, specifically coronary artery disease, stroke, peripheral artery disease, heart failure, infective endocarditis and rheumatic heart disease. We discuss the various mechanisms by which oral dysbiosis contributes to CVD pathogenesis and potential strategies for prevention and treatment.
Keyphrases
- cardiovascular disease
- heart failure
- coronary artery disease
- endothelial cells
- high throughput
- peripheral artery disease
- atrial fibrillation
- systematic review
- type diabetes
- public health
- induced pluripotent stem cells
- left ventricular
- cardiovascular events
- percutaneous coronary intervention
- risk factors
- pluripotent stem cells
- metabolic syndrome
- human health
- acute coronary syndrome
- aortic valve
- replacement therapy